Overview of one-month treatment cost of pemetinib/pemetinib

Pemigatinib/Pemigatinib, a revolutionary FGFR1-3 inhibitor, brings new hope to patients with locally advanced or metastatic cholangiocarcinoma (CCA) who have received treatment but failed to respond to surgery and are unresectable. The drug is unique in that it targets patients whose FGFR2 fusions or other rearrangements are confirmed by an FDA-approved test. In the treatment plan, patients need to take 13.5mg of pemetinib regularly every day, taking it for 14 days and then stopping for 7 days to complete a treatment cycle. Such periodic treatment helps patients gain relief from the effects of the medication while also allowing the body enough time to recover.

For many patients and their families, the cost of pemetinib treatment is an issue that cannot be ignored. At present, the original drug of pemetinib has been launched in the Chinese market, but it has not been covered by medical insurance, so patients need to bear the full cost of the drug. According to market pricing, the price of pemetinib per box with a specification of 9mg*14 tablets may be as high as about 50,000 yuan. Based on this calculation, the patient's monthly treatment cost may be close to 100,000 yuan, which is undoubtedly a heavy financial burden for many families. At the same time, there are also differences in the prices of the original drug pemetinib in overseas markets. The price of each box of pemetinib with a specification of 13.5mg*14 tablets may be around RMB 70,000, but the actual price may change due to factors such as exchange rate fluctuations.

In addition to the original drug, there are also some generic pemetinib drugs produced by other countries on the overseas market. These generic drugs are basically the same as the original drugs in terms of drug ingredients, but the prices are relatively affordable. For example, a pharmaceutical factory in Laos produces generic pemetinib with a specification of 4.5mg*14 tablets, and the price per box may be more than 1,000 yuan. Based on this calculation, the patient’s monthly treatment cost may be significantly reduced to less than 10,000 yuan.